Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

The Hospital Anxiety and Depression Scale

Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026

Molecular characterization of a peripheral receptor for cannabinoids

Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475

Cannabinoid physiology and pharmacology: 30 years of progress

Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608

The metabolic syndrome—a new worldwide definition

Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655

Obesity

Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097

Anti-obesity drug discovery: advances and challenges

Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021

The Effects of Diet on Inflammation

Giugliano, D., Ceriello, A., & Esposito, K. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.052 · Cited by 842

Drug treatments for obesity: orlistat, sibutramine, and rimonabant

Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753

Activation of the peripheral endocannabinoid system in human obesity

Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686

Drug addiction: the neurobiology of disrupted self-control

Baler, R. D., & Volkow, N. D. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.005 · Cited by 640

Hypertriglyceridemia: its etiology, effects and treatment

Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436

Secondary metabolism in cannabis

Flores-Sanchez, I. J., & Verpoorte, R. (2008) · Phytochemistry Reviews · doi:10.1007/s11101-008-9094-4 · Cited by 400

Early phytocannabinoid chemistry to endocannabinoids and beyond

Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393

Long-term pharmacotherapy for obesity and overweight

Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384

The Evolution of Very‐Low‐Calorie Diets: An Update and Meta‐analysis

Tsai, A. G., & Wadden, T. A. (2006) · Obesity · doi:10.1038/oby.2006.146 · Cited by 371

Endocannabinoids–at the crossroads between the gut microbiota and host metabolism

Cani, P. D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N. M., Druart, C., & Everard, A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.211 · Cited by 367

Review article: The impact of obesity on reproduction in women with polycystic ovary syndrome

Pasquali, R., Gambineri, A., & Pagotto, U. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00990.x · Cited by 359

Progress and challenges in anti-obesity pharmacotherapy

Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347

Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress

Bortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347

Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat

Davis, J. F., Tracy, A. L., Schurdak, J. D., Tschöp, M. H., Lipton, J. W., Clegg, D. J., & Benoit, S. C. (2008) · Behavioral Neuroscience · doi:10.1037/a0013111 · Cited by 307

Lifestyle Intervention for Prevention of Type 2 Diabetes in Primary Health Care

Saaristo, T., Moilanen, L., Korpi-Hyövälti, E., Vanhala, M., Saltevo, J., Niskanen, L., Jokelainen, J., Peltonen, M., Oksa, H., Tuomilehto, J., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0410 · Cited by 302

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60935-x · Cited by 266

Pharmacotherapy of obesity: available medications and drugs under investigation.

Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248

Treatment Modalities of Obesity

Hainer, V., Toplak, H., & Mitrakou, A. (2008) · Diabetes Care · doi:10.2337/dc08-s265 · Cited by 231

Rimonabant: From RIO to Ban

Sam, A. H., Salem, V., & Ghatei, M. A. (2011) · Journal of Obesity · doi:10.1155/2011/432607 · Cited by 230

Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity

Moreno, B., Bellido, D., Sajoux, I., Goday, A., Saavedra, D., Crujeiras, A. B., & Casanueva, F. F. (2014) · Endocrine · doi:10.1007/s12020-014-0192-3 · Cited by 222

Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders

Gorzalka, B. B., Hill, M. N., & Hillard, C. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.004 · Cited by 211

Abdominal obesity: The most prevalent cause of the metabolic syndrome and related cardiometabolic risk

Després, J.-P. (2006) · European Heart Journal Supplements · doi:10.1093/eurheartj/sul002 · Cited by 205

Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function

Cota, D., Steiner, M.-A., Marsicano, G., Cervino, C., Herman, J. P., Grübler, Y., Stalla, J., Pasquali, R., Lutz, B., Stalla, G. K., et al. (2007) · Endocrinology · doi:10.1210/en.2005-1649 · Cited by 205

Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease

Moreno, B., Crujeiras, A. B., Bellido, D., Sajoux, I., & Casanueva, F. F. (2016) · Endocrine · doi:10.1007/s12020-016-1050-2 · Cited by 204

Anti-obesity therapy: from rainbow pills to polyagonists

Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199

Causality of small and large intestinal microbiota in weight regulation and insulin resistance

Scheithauer, T. P. M., Dallinga-Thie, G. M., de Vos, W. M., Nieuwdorp, M., & van Raalte, D. H. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.002 · Cited by 188

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal, L. F., Scheen, A. J., Rissanen, A. M., Rössner, S., Hanotin, C., & Ziegler, O. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn076 · Cited by 156

Centrally Acting Agents for Obesity: Past, Present, and Future

Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151

Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: Systematic review and mixed treatment comparison meta-analysis

Dunkley, A. J., Charles, K., Gray, L. J., Camosso‐Stefinovic, J., Davies, M. J., & Khunti, K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01571.x · Cited by 151

Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse

Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148

Therapeutic potential of cannabis-related drugs

Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149

Mitochondrial uncouplers with an extraordinary dynamic range

Lou, P.-H., Hansen, B. S., Olsen, P. H., Tullin, S., Murphy, M. P., & Brand, M. D. (2007) · Biochemical Journal · doi:10.1042/bj20070606 · Cited by 141

Treatment of nicotine addiction: present therapeutic options and pipeline developments

Polosa, R., & Benowitz, N. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.008 · Cited by 135

Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis

Li, B., Li, W., Li, X., & Zhou, H. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230142931 · Cited by 130

New targets to treat obesity and the metabolic syndrome

Martin, K. A., Mani, M. V., & Mani, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.093 · Cited by 121

Drug Treatment of the Overweight Patient

Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115

Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients With Nonconstipated Irritable Bowel Syndrome

Wong, B. S., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L. A., Burton, D., & Zinsmeister, A. R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.036 · Cited by 100

Diet and nutrition in polycystic ovary syndrome (PCOS): Pointers for nutritional management

Farshchi, H., Rane, A., Love, A., & Kennedy, R. L. (2007) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443610701667338 · Cited by 87

Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders

Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86

Effect of anti-obesity drug on cardiovascular risk factors: A systematic review and meta-analysis of randomized controlled trials

Zhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039062 · Cited by 84

Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.

Schindler, C. W., Redhi, G. H., Vemuri, K., Makriyannis, A., Le Foll, B., Bergman, J., Goldberg, S. R., & Justinova, Z. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.27 · Cited by 73

Long-term effects of weight-reducing drugs in people with hypertension

Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen, A. J. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01681.x · Cited by 68

Thermogenic and metabolic antiobesity drugs: rationale and opportunities

Clapham, J. C., & Arch, J. R. S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00608.x · Cited by 60

Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways

Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C., Tokuyama, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807120200 · Cited by 53

Structure elucidation of the tetrahydrocannabinol complex with randomly methylated β-cyclodextrin.

Hazekamp, A., & Verpoorte, R. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.07.001 · Cited by 52

Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents

Terry, G., Liow, J.-S., Chernet, E., Zoghbi, S. S., Phebus, L., Felder, C. C., Tauscher, J., Schaus, J. M., Pike, V. W., Halldin, C., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.004 · Cited by 51

The Treatment of Obesity and Its Co-Occurrence With Substance Use Disorders

VanBuskirk, K. A., & Potenza, M. N. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181ce38e7 · Cited by 48

Androgens, Obesity, and Sleep-Disordered Breathing in Men

Liu, P. Y., Caterson, I. D., Grunstein, R. R., & Handelsman, D. J. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.03.002 · Cited by 43

Role of the endocannabinoid system in metabolic control

Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17

Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS)

Sathyapalan, T., Cho, L. W., Kilpatrick, E. S., Coady, A., & Atkin, S. L. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03345.x · Cited by 11

Fundamentals of Cardipmetabolic Risk Factor Reduction: Achieving and Maintaining Weight Loss with Pharmacotherapy or Bariatric Surgery

Fabbrini, E., & Klein, S. (2008) · Clinical Cornerstone · doi:10.1016/s1098-3597(08)60027-7 · Cited by 9

Chapter 4.5 The endocannabinoid system and anxiety responses

Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7